MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-29-2026
NovaBay Pharmaceuticals Operating Income 2011-2026 | NBY
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income NovaBay Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.44 M | -7.38 M | -4.1 M | -14.4 M | -8.86 M | -6.43 M | -9.4 M | -7.87 M | -7.31 M | -11 M | -21.1 M | -16.9 M | -15.5 M | -8.31 M | -4.32 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.1 M | -21.1 M | -10.1 M |
Quarterly Operating Income NovaBay Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.26 M | -1.89 M | -3.29 M | - | -1.7 M | -1.62 M | -2.29 M | - | -698 K | -1.05 M | -1.34 M | - | -457 K | -2.15 M | -2.38 M | - | -2.29 M | -1.86 M | -1.52 M | - | -2.06 M | -1.07 M | -1.54 M | - | -1.71 M | -1.38 M | -4.07 M | - | -1.81 M | -2.08 M | -2.37 M | - | -2.17 M | -1.76 M | -3.78 M | - | -2.06 M | -2.24 M | -4.65 M | - | -5.35 M | -4.86 M | -4.66 M | - | -4.11 M | -3.79 M | -4.08 M | - | -2.98 M | -4.15 M | -3.49 M | - | -106 K | -2.88 M | -2.48 M | - | -348 K | 440 K | -1.94 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 440 K | -5.35 M | -2.34 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
60.3 M | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
872 M | $ 46.48 | 4.64 % | $ 12.6 B | USA |
 |
Fortress Biotech
FBIO
|
-70.2 M | $ 2.5 | 1.63 % | $ 69.8 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | France |
 |
Athira Pharma
ATHA
|
-102 M | - | - | $ 269 M | USA |
 |
Galapagos NV
GLPG
|
-166 M | $ 28.79 | 1.41 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
2.64 B | $ 27.79 | 0.92 % | $ 17.1 B |  Danmark |
 |
Genprex
GNPX
|
-15.5 M | $ 0.9 | 1.12 % | $ 839 K | USA |
 |
Grifols, S.A.
GRFS
|
595 M | $ 8.33 | 0.73 % | $ 6.83 B |  Spain |
 |
Immuron Limited
IMRN
|
-2.87 M | $ 0.8 | 1.39 % | $ 6.7 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
-214 M | $ 76.27 | 1.36 % | $ 12.2 B | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 95.08 | -0.44 % | $ 27.2 B | Germany |
 |
Kamada Ltd.
KMDA
|
-696 K | $ 8.28 | 0.85 % | $ 260 M |  Israel |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | USA |
 |
Kymera Therapeutics
KYMR
|
-349 M | $ 85.67 | 3.58 % | $ 7.24 B | USA |
 |
INmune Bio
INMB
|
-47.4 M | $ 1.54 | - | $ 38.1 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-22.6 M | $ 232.25 | -0.02 % | $ 4.25 B | USA |
 |
Liquidia Corporation
LQDA
|
-51.4 M | $ 41.83 | 4.24 % | $ 3.6 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
231 M | $ 22.89 | 2.42 % | $ 3.79 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-22.1 M | $ 108.2 | 2.26 % | $ 5.43 B | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
MannKind Corporation
MNKD
|
38.8 M | $ 3.84 | 34.27 % | $ 1.17 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 3.51 | 0.29 % | $ 5.78 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 23.68 | 1.09 % | $ 3.01 B | USA |
 |
Nanobiotix S.A.
NBTX
|
-52.6 M | $ 41.17 | 18.39 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |